Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 03/07/20 at 10:25am

Gilead features prominently in the news this week, as the US bought most of the world’s stock of the company’s drug remdesivir, which is one of the only drugs proven to treat COVID-19, while announcing it will charge $2,340 for a 5 day course of the treatment.

In other news, Pfizer has filed a lawsuit against the US government to allow it to directly help with the copayments of Medicare recipients for the company’s cardiovascular drugs while the National Institutes of Health had its funding cut from a research project into bat coronavirus, according its Director Dr Anthony Fauci.

1. NIH ordered to cancel coronavirus research funding by White House, Dr Fauci tells Congress

The National Institutes of Health had its funding cut from a research project into bat coronavirus, according its Director Dr Anthony Fauci.

2. UK Government accused of withholding Pillar 2 COVID-19 data which show Leicester had 10 times more cases than reported pre-lockdown

The UK Government warned when relaxing lockdown measures on 23 June that it would not hesitate to lock down any region which began to show an uncontrolled rise in COVID-19 cases.

3. Vaxart announces its COVID-19 vaccine has been selected by US Operation Warp Speed programme

Vaxart has announced the selection of its lead vaccine candidate for COVID-19 by Operation Warp Speed, a program to find a vaccine for the US by the end of the year.

4. COVID-19 immunity may be more widespread than previously thought, new study suggests

Coronavirus immunity in the world’s population may be more widespread than initially thought, even in those who have tested negative for antibodies, a new study suggests.

5. Pfizer sues US for permission to help Medicare patients with rare heart conditions

Pfizer has filed a lawsuit against the US government to allow it to directly help with the copayments of Medicare recipients for the company’s cardiovascular drugs.

6. AstraZeneca continues to ramp up COVID-19 vaccine production with new CMO partnership

AstraZeneca has continued to build its manufacturing capacity to deliver its COVID-19 vaccine candidate, developed in partnership with the University of Oxford and currently being tested in human trials across a number of trials across the UK, with its latest partnership signed with Scottish firm Symbiosis Pharmaceutical Services.

7. US buys most of the world’s stock of COVID-19 drug remdesivir

The US has bought most of the world’s stock of the drug remdesivir which is one of the only drugs proven to treat COVID-19.

8. China’s COVID-19 vaccine candidate approved for military use

China’s military have received approval to use a new vaccine candidate for coronavirus after clinical trials proved it was safe and showed some efficacy.

9. FDA rejects Allergan's Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns

The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, Abicipar pegol, as treatment for the eye condition known as neovascular age-related macular degeneration (nAMD).

10. Gilead facing criticism for charging $2,340 for remdesivir

Gilead has announced that it will charge $2,340 for a 5 day treatment course of remdesivir, a drug that has been proven to reduce the symptoms of COVID-19.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches